Cardiovascular–kidney–metabolic syndrome: novel molecular mechanism and glucagon-like peptide-1-targeting therapy
Cardiovascular–kidney–metabolic (CKM) syndrome represents a systemic disease continuum arising from the progressive and reciprocal interactions among metabolic dysfunction, kidney injury, and cardiovascular disease.